NCT04133415

Palliative Lattice Stereotactic Body Radiotherapy (SBRT)

A Trial of Palliative Lattice Stereotactic Body Radiotherapy (SBRT)

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Washington University School of Medicine · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Standard palliative radiotherapy regimens may provide limited durability of response in large tumors. Thus, there is a clinical need for a new approach. The Lattice SBRT approach will deliver 20 Gy in 5 fractions with partial volume simultaneous integrated boosts to 66.7 Gy. This is hypothesized to improve symptom response, local control, and better prime the tumor microenvironment for immune response compared with standard palliative radiotherapy doses. It is also hypothesized that this will be associated with less toxicity than the traditional homogenous SBRT plan delivered to a large tumor. Blood will be collected before and after Lattice SBRT for evaluation of the peripheral blood immune microenvironment.

Conditions

• Cancer
• Palliative Radiotherapy

Interventions

Type	Name	Description
RADIATION	Lattice stereotactic body radiation therapy	-As long as radiotherapy fields do not overlap, treatment of up to 4 other tumor sites are allowed
PROCEDURE	Peripheral blood	-Before treatment, immediately after radiotherapy completion, 14 days after radiotherapy, and 30 days after radiotherapy

Timeline

• Start date: 2019-10-31
• Primary completion: 2020-12-14
• Completion: 2020-12-14
• First posted: 2019-10-21
• Last updated: 2021-11-22
• Results posted: 2021-11-22

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated device study